Last reviewed · How we verify
ETEC/rCTB vaccine
This vaccine stimulates immune responses against enterotoxigenic E. coli (ETEC) by presenting the recombinant cholera toxin B subunit (rCTB) as an immunogen to prevent ETEC-induced diarrhea.
This vaccine stimulates immune responses against enterotoxigenic E. coli (ETEC) by presenting the recombinant cholera toxin B subunit (rCTB) as an immunogen to prevent ETEC-induced diarrhea. Used for Prevention of enterotoxigenic E. coli (ETEC)-induced diarrhea in travelers and military personnel.
At a glance
| Generic name | ETEC/rCTB vaccine |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Drug class | vaccine |
| Target | ETEC colonization factors and enterotoxins; GM1 ganglioside receptor |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses rCTB as a carrier and adjuvant to enhance mucosal and systemic immune responses against ETEC colonization factors and toxins. rCTB binds to GM1 ganglioside receptors on intestinal epithelial cells, promoting uptake and presentation to the immune system. This approach aims to induce protective antibodies and cellular immunity that prevent ETEC infection and toxin-mediated secretory diarrhea.
Approved indications
- Prevention of enterotoxigenic E. coli (ETEC)-induced diarrhea in travelers and military personnel
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Gastrointestinal symptoms (mild diarrhea, nausea)
- Headache
- Fatigue
Key clinical trials
- Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children (PHASE3)
- Mucosal Response in Immunocompromised Host (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETEC/rCTB vaccine CI brief — competitive landscape report
- ETEC/rCTB vaccine updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI